Report cover image

Global Recombinant Protein Therapeutics CDMO Market Size- By Type, By Source, By Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published May 23, 2025
Length 259 Pages
SKU # SPER20187032

Description

Recombinant Protein Therapeutics CDMO Market Introduction and Overview

According to SPER market research, ‘Global Recombinant Protein Therapeutics CDMO Market Size- By Type, By Source, By Indication – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Recombinant Protein Therapeutics CDMO Market is predicted to reach 90.1 billion by 2034 with a CAGR of 14.21%.

A recombinant protein therapeutics contract development and manufacturing organization (CDMO) offers specialized services for developing and manufacturing recombinant protein-based therapeutics. These biologic drugs are made by genetically engineering cells to produce therapeutic proteins. CDMOs support pharmaceutical and biotechnology companies with various tailored services.

Restraints:

Recombinant Protein Therapeutics are manufactured using highly sophisticated methods that necessitate cutting-edge technology and specialised facilities. To ensure safety, efficacy, and quality, these production stages must comply with severe regulatory requirements. As a result, production costs are far greater than for typical medications. Establishing and maintaining conformity with global regulatory frameworks like the FDA, EMA, and ICH adds to the financial burden.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered

By Type, By Source, By Indication

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Richter-Helm BioLogics, Lonza, Catalent, Inc, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, Curia Global, Inc, Batavia Biosciences B.V, HALIX B.V, BIOVIAN, Enzene Biosciences Ltd.

Global Recombinant Protein Therapeutics CDMO Market Segmentation:

By Type: Based on the Type, Global Recombinant Protein Therapeutics CDMO Market is segmented as; Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others.

By Source: Based on the Source, Global Recombinant Protein Therapeutics CDMO Market is segmented as; Mammalian Systems, Microbial Systems, Others.

By Indication: Based on the Indication, Global Recombinant Protein Therapeutics CDMO Market is segmented as; Oncology, Infectious Diseases, Immunological Disorders, Metabolic Disorders, Hematological Disorders, Others.

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

259 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2 Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3 Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Recombinant Protein Therapeutics CDMO Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Recombinant Protein Therapeutics CDMO Market
7. Global Recombinant Protein Therapeutics CDMO Market, By Type (USD Million) 2021-2034
7.1. Growth Hormones
7.2. Interferons
7.3. Vaccines
7.4. Immunostimulating Agents
7.5. Others
8. Global Recombinant Protein Therapeutics CDMO Market, By Source (USD Million) 2021-2034
8.1. Mammalian Systems
8.2. Microbial Systems
8.3. Others
9. Global Recombinant Protein Therapeutics CDMO Market, By Indication (USD Million) 2021-2034
9.1. Oncology
9.2. Infectious Diseases
9.3. Immunological Disorders
9.4. Metabolic Disorders
9.5. Haematological Disorders
9.6. Others
10. Global Recombinant Protein Therapeutics CDMO Market, (USD Million) 2021-2034
10.1. Global Recombinant Protein Therapeutics CDMO Market Size and Market Share
11. Global Recombinant Protein Therapeutics CDMO Market, By Region, (USD Million) 2021-2034
11.1. Asia-Pacific
11.1.1. Australia
11.1.2. China
11.1.3. India
11.1.4. Japan
11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia
11.3.2. United Arab Emirates
11.3.3. Qatar
11.3.4. South Africa
11.3.5. Egypt
11.3.6. Morocco
11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada
11.4.2. Mexico
11.4.3. United States
11.5. Latin America
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
12. Company Profile
12.1. Richter-Helm BioLogics
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Lonza
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Catalent, Inc
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. FUJIFILM Diosynth Biotechnologies
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. WuXi Biologics
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Curia Global, Inc
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Batavia Biosciences B. V
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. HALIX B. V
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. BIOVIAN
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Enzene Biosciences Ltd
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us